AKBA Akebia Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1517022 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-12.4%
TTM net income YoY-180.2%
TTM EPS YoY-112.5%
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—
Margins
Gross margin78.9%
Operating margin-15.7%
Net margin-22.6%
FCF margin7.0%
EBITDA margin-15.1%
Returns
ROE-143.8%
ROA-12.6%
ROIC (approx.)—
Asset turnover0.56x
Leverage & solvency
Liabilities / assets94.0%
Debt / equity2.47x
Current ratio1.36x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.35x
Accruals ratio-17.1%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $236.20M | $160.18M | $194.62M | $292.48M | $211.65M |
| Cost of revenue | $39.46M | $63.18M | $74.15M | $85.57M | $150.67M |
| Gross profit | $196.73M | $97.00M | $120.47M | $206.92M | $60.98M |
| R&D expense | $62.36M | $37.65M | $63.08M | $129.99M | $147.85M |
| SG&A expense | $107.48M | $106.55M | $100.23M | $138.60M | $174.14M |
| Operating income | $23.50M | -$50.47M | -$46.26M | -$80.78M | -$264.50M |
| Pretax income | -$3.72M | -$69.41M | -$51.92M | -$94.23M | -$282.02M |
| Income tax | $1.62M | $0 | $0 | $0 | $0 |
| Net income | -$5.34M | -$69.41M | -$51.92M | -$94.23M | -$282.02M |
| EBITDA | $24.77M | -$49.01M | -$44.67M | -$79.12M | -$262.57M |
| EPS (basic) | -0.02 | -0.33 | -0.28 | -0.52 | -1.70 |
| EPS (diluted) | -0.02 | -0.33 | -0.28 | -0.52 | -1.70 |
| Weighted avg. shares (diluted) | 257.16M | 210.95M | 187.47M | 182.78M | 165.95M |
| Balance sheet | |||||
| Cash & equivalents | $184.84M | $53.55M | $42.92M | $93.17M | $151.84M |
| Receivables | $47.03M | $34.37M | $39.29M | $40.28M | $51.58M |
| Inventory | $15.61M | $16.24M | $15.69M | $21.57M | $36.63M |
| Current assets | $252.96M | $113.83M | $118.15M | $185.18M | $271.15M |
| PP&E, net | $1.22M | $2.20M | $3.63M | $5.21M | $6.75M |
| Goodwill | $59.04M | $59.04M | $59.04M | $59.04M | $59.04M |
| Intangibles | — | $0 | $36.04M | $72.08M | $108.13M |
| Total assets | $376.56M | $220.67M | $241.70M | $356.05M | $529.35M |
| Current liabilities | $162.94M | $80.91M | $99.87M | $129.54M | $261.05M |
| Short-term debt | $0 | $0 | $17.50M | $32.00M | $97.54M |
| Long-term debt | $48.25M | $38.69M | $17.18M | $34.08M | $0 |
| Total debt | $48.25M | $38.69M | $34.68M | $66.08M | $97.54M |
| Total liabilities | $343.95M | $269.86M | $272.29M | $350.82M | $455.34M |
| Shareholders' equity | $32.61M | -$49.19M | -$30.58M | $5.23M | $74.01M |
| Net debt | -$136.59M | -$14.86M | -$8.24M | -$27.09M | -$54.30M |
| Shares outstanding | 265.42M | 224.85M | 194.58M | 184.14M | 177.00M |
| Cash flow statement | |||||
| Operating cash flow | $67.99M | -$40.66M | -$23.38M | -$73.15M | -$252.97M |
| Capital expenditure | $291,000 | $33,000 | $0 | $114,000 | $59,000 |
| Free cash flow | $67.70M | -$40.69M | -$23.38M | -$73.27M | -$253.02M |
| Investing cash flow | -$7.93M | -$33,000 | $0 | -$114,000 | $39.94M |
| Financing cash flow | $72.93M | $49.66M | -$25.21M | $14.60M | $133.73M |
| Depreciation & amortization | $1.27M | $1.46M | $1.58M | $1.65M | $1.93M |
| Stock-based compensation | $11.28M | $7.78M | $9.32M | $17.85M | $22.73M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.